Clinical Trial Update: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) [Phase 3]

View source ↗

Summary

A Phase 3 study (RECHARGE 1) to assess the efficacy, safety, and tolerability of remibrutinib in adults and adolescents with moderate to severe hidradenitis sup…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: RECRUITING